SRZN · Surrozen, Inc./DE
$29.13
-0.19 (-0.65%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$347.20M
Shares
11.75M
Volume · Oct 5
439.18K
Avg daily vol (3M)
458.68K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.13
Open$29.32
Day$26.97–29.70
52W close$11.80–34.13
Avg vol 30d722K
Short int2.2M · 18.7% float · 12.7d
Short vol65%
Last earningsMar 22, 2023
DataJan 2021–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held Mar 22, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$11.51M
Trailing 12 months
Net income (TTM)
−$332.13M
Trailing 12 months
Revenue growth YoY
+408.6%
Year over year
Operating margin
-385.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+171.0%
Year over year · more shares
Price change (1Y)
+112.9%
Trailing year
Short interest
18.7%
Latest settlement · 12.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+27%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
−9%
trailing
YTD return
+29%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $25 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$6.9M over 90 days · 100% sells
Short interest
Rising
18.68% of float · ▲ +51.9% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−67%
Y/Y
EPS growth
−49%
Y/Y
Free cash flow
$-30.4M
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+27%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $23 › 200d $25 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$6.9M over 90 days · 100% sells
Short interest
Rising
18.68% of float · ▲ +51.9% MoM · 12.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $29 · 78%
Range high $34
vs 200-day avg +18%
vs 50-day avg +27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRZN
this stock
Surrozen, Inc./DE
|
$347.20M | +28.9% | -67.4% | — | 18.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRZN | -1.7% | +28.0% | -8.5% | -9.5% | +28.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -2.9% | +27.4% | -20.1% | -11.1% | +15.3% |